Compare Core Scientific Inc (CORZ) vs Quest Diagnostics Inc (DGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Core Scientific Inc vs Quest Diagnostics Inc — how do they compare? Core Scientific Inc trades at $15.12 (market cap $4.94B), while Quest Diagnostics Inc trades at $231.03 (market cap $25.48B). The key difference: Quest Diagnostics Inc is far larger — about 5.2× Core Scientific Inc's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while Core Scientific Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Core Scientific Inc for 20 Days and Quest Diagnostics Inc for 56 Days on average.
| CORZ | DGX | |
|---|---|---|
Market Cap | $4.94B | $25.48B |
Volume | 15,630,800 | 941,866 |
Sector | Technology | Health |
52-Week High | $29.16 | $247.45 |
52-Week Low | $13.57 | $173.49 |
Typical Hold Time | 20 Days | 56 Days |
Enterprise Value | $7.46B | $31.23B |
Dividend Yield | — | 1.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CORZ trades at $15.25, down 4.36% today amid a bearish technical trend. The stock shows weak fundamentals with a net loss of $288.62 million in 2025 and negative profit margins, though revenue is projected to grow to $440 million in 2026. Analyst sentiment remains strongly bullish with an 86% buy rating and a $32.75 consensus price target, but recent earnings misses and high cash burn pose significant risks.
The outlook is mixed: strong analyst support and insider buying suggest confidence in the AI data center strategy, but persistent losses, negative cash flow, and competitive pressures require careful monitoring. The stock's current price near support levels offers potential upside if execution improves, yet volatility and operational challenges present substantial downside risk.
Quest Diagnostics (DGX) trades at $227.00, down 0.64% with a bearish technical signal. The company shows strong fundamentals with three consecutive quarterly earnings beats and revenue growth from $9.9B in 2024 to $11.0B in 2025. Recent developments include positive clinical study results and a new Apple Health integration, though Medicare reimbursement cuts pose headwinds. The stock trades near support at $226 with oversold RSI readings suggesting potential for near-term bounce.
DGX presents a mixed outlook with solid execution offset by regulatory risks. The 10% upside to consensus price target of $250 offers opportunity, but Medicare payment reductions and rising debt levels require monitoring. Recent earnings momentum and strategic partnerships support growth, making DGX suitable for investors comfortable with healthcare sector volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Core Scientific Inc
Core Scientific provides digital infrastructure for Bitcoin mining and high-performance computing (HPC). It operates purpose-built data centers to support digital asset production and AI-related workloads.
Read more on CORZ →About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →
